|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
US10886309B2
(en)
|
2015-11-06 |
2021-01-05 |
Artilux, Inc. |
High-speed light sensing apparatus II
|
|
US10418407B2
(en)
|
2015-11-06 |
2019-09-17 |
Artilux, Inc. |
High-speed light sensing apparatus III
|
|
US10254389B2
(en)
|
2015-11-06 |
2019-04-09 |
Artilux Corporation |
High-speed light sensing apparatus
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11105928B2
(en)
|
2018-02-23 |
2021-08-31 |
Artilux, Inc. |
Light-sensing apparatus and light-sensing method thereof
|
|
US11482553B2
(en)
|
2018-02-23 |
2022-10-25 |
Artilux, Inc. |
Photo-detecting apparatus with subpixels
|
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
TWI780007B
(zh)
|
2018-04-08 |
2022-10-01 |
美商光程研創股份有限公司 |
光偵測裝置及其系統
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
CA3103185A1
(en)
|
2018-06-13 |
2019-12-19 |
Amphista Therapeutics Ltd |
Bifunctional molecules for targeting rpn11
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3864030A4
(en)
*
|
2018-10-12 |
2022-09-21 |
The Scripps Research Institute |
Compounds and methods for dcaf-mediated protein degradation
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
US12384776B2
(en)
|
2019-01-29 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP3917517A4
(en)
|
2019-01-29 |
2023-01-25 |
Foghorn Therapeutics Inc. |
CONNECTIONS AND USES THEREOF
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
KR102947433B1
(ko)
|
2019-04-12 |
2026-04-06 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP4069726A4
(en)
|
2019-12-04 |
2024-03-20 |
The Scripps Research Institute |
GLP2 RECEPTOR AGONISTS AND METHOD OF USE
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP7871189B2
(ja)
*
|
2019-12-17 |
2026-06-08 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質の動員および／または分解を調節する化合物
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
US20240024490A1
(en)
*
|
2021-04-09 |
2024-01-25 |
The Broad Institute, Inc. |
Bifunctional molecules for selective modification of target substrates
|
|
EP4323340A2
(en)
|
2021-04-13 |
2024-02-21 |
President and Fellows of Harvard College |
E3 ligase binders and uses thereof
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
BR112023024507A2
(pt)
|
2021-05-26 |
2024-02-15 |
C4 Therapeutics Inc |
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
|
|
AU2022289610A1
(en)
|
2021-06-09 |
2024-01-25 |
The Scripps Research Institute |
Long-acting dual gip/glp-1 peptide conjugates and methods of use
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
KR20240111312A
(ko)
|
2021-10-25 |
2024-07-16 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Tyk2 분해제 및 이의 용도
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
CN122206684A
(zh)
|
2023-06-30 |
2026-06-12 |
默克专利有限公司 |
用于kras蛋白降解的异双功能化合物
|
|
JP2026524477A
(ja)
|
2023-06-30 |
2026-07-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｋｒａｓの分解のためのヘテロ二官能性化合物
|
|
WO2026107062A1
(en)
|
2024-11-13 |
2026-05-21 |
Recludix Pharma, Inc. |
Stat6 degraders and uses thereof
|
|
WO2026139448A1
(en)
|
2024-12-23 |
2026-07-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|